F M Mottaghy
Overview
Explore the profile of F M Mottaghy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van de Weijer T, Bemer F, de Vos-Geelen J, Hermans B, Mitea C, van der Pol J, et al.
Eur J Nucl Med Mol Imaging
. 2024 Feb;
51(8):2420-2427.
PMID: 38403723
Purpose: The need for an interval between the administration of long-acting Somatostatin Receptor Analogues (SSA) and the [Ga]Ga-DOTA-TATE PET has been questioned based on recent literature in the new EANM...
2.
3.
Ibrahim A, Primakov S, Beuque M, Woodruff H, Halilaj I, Wu G, et al.
Methods
. 2020 Jun;
188:20-29.
PMID: 32504782
The advancement of artificial intelligence concurrent with the development of medical imaging techniques provided a unique opportunity to turn medical imaging from mostly qualitative, to further quantitative and mineable data...
4.
Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Bohme C, Burchert W, et al.
Urologe A
. 2018 Apr;
57(6):709-713.
PMID: 29671080
In the last 3 years, Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA-RLT) has received increasing attention in nuclear medicine as a new form of treatment for castration-resistant metastatic prostate cancer....
5.
Beheshti M, Mottaghy F, Paycha F, Behrendt F, Van den Wyngaert T, Fogelman I, et al.
Eur J Nucl Med Mol Imaging
. 2017 Nov;
45(2):322.
PMID: 29130115
The original version of this article unfortunately contained an error. The name and affiliation of "Frédéric Paycha" needs to be corrected. Given in this article is the correct author name...
6.
Wierts R, Jentzen W, Quick H, Wisselink H, Pooters I, Wildberger J, et al.
Phys Med Biol
. 2017 Nov;
63(1):015014.
PMID: 29116052
The aim was to investigate the quantitative performance of I PET/MRI for pre-therapy lesion dosimetry in differentiated thyroid cancer (DTC). Phantom measurements were performed on a PET/MRI system (Biograph mMR,...
7.
8.
van Nijnatten T, Goorts B, Voo S, de Boer M, Kooreman L, Heuts E, et al.
Eur J Nucl Med Mol Imaging
. 2017 Sep;
45(2):179-186.
PMID: 28905091
Purpose: To investigate the feasibility and potential added value of dedicated axillary 18F-FDG hybrid PET/MRI, compared to standard imaging modalities (i.e. ultrasound [US], MRI and PET/CT), for axillary nodal staging...
9.
Lheureux S, Denoyelle C, Ohashi P, de Bono J, Mottaghy F
Eur J Nucl Med Mol Imaging
. 2017 Apr;
44(Suppl 1):41-54.
PMID: 28396911
Molecular imaging continues to influence every aspect of cancer care including detection, diagnosis, staging and therapy response assessment. Recent advances in the understanding of cancer biology have prompted the introduction...
10.
Verwer E, Zegers C, Van Elmpt W, Wierts R, Windhorst A, Mottaghy F, et al.
EJNMMI Phys
. 2016 Dec;
3(1):30.
PMID: 27957730
Background: [F]HX4 is a promising new PET tracer developed to identify hypoxic areas in tumor tissue. This study analyzes [F]HX4 kinetics and assesses the performance of simplified methods for quantification...